Prescriber's Corner
For access to the full length article, please sign in.
New Agents in the Treatment of Multiple Myeloma
Beth Faiman,(1) PhD, MSN, APRN-BC, AOCN®, Ali McBride,(2) PharmD, MS, BCPS, BCOP, Hollie Devine,(3) MSN, ANP-BC, Charise Gleason,(4) MSN, NP-BC, AOCNP®, and Sandra Kurtin,(5) RN, MSN, AOCN®, ANP-C, on behalf of the International Myeloma Foundation Nurse Leadership Board
1Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio; 2The University of Arizona Cancer Center, Tuscon, Arizona; 3The Ohio State University Medical Center, Columbus, Ohio; 4Emory University, Atlanta, Georgia
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, Cleveland Clinic Taussig Cancer Institute, Multiple Myeloma Program, 9500 Euclid Avenue, Cleveland, OH 44195.
E-mail: faimanb@ccf.org
Authors' disclosures of potential conflicts of interest are found at the end of this article
J Adv Pract Oncol 2016;7:45–52 | doi: 10.6004/jadpro.2016.7.2.13 | © 2016 Harborside Press®
1Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio; 2The University of Arizona Cancer Center, Tuscon, Arizona; 3The Ohio State University Medical Center, Columbus, Ohio; 4Emory University, Atlanta, Georgia
Beth Faiman, PhD, MSN, APRN-BC, AOCN®, Cleveland Clinic Taussig Cancer Institute, Multiple Myeloma Program, 9500 Euclid Avenue, Cleveland, OH 44195.
E-mail: faimanb@ccf.org
Authors' disclosures of potential conflicts of interest are found at the end of this article
J Adv Pract Oncol 2016;7:45–52 | doi: 10.6004/jadpro.2016.7.2.13 | © 2016 Harborside Press®
For access to the full length article, please sign in.